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Abstract
Reducing the risk of dementia can halt the worldwide increase of affected people. The
multifactorial and heterogeneous nature of late-onset dementia, including Alzheimer’s
disease (AD), indicates a potential impact of multidomain lifestyle interventions on risk
reduction. The positive results of the landmark multidomain Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER) support such
an approach. The World-Wide FINGERS (WW-FINGERS), launched in 2017 and including over 25 countries, is the first global network of multidomain lifestyle intervention trials for dementia risk reduction and prevention. WW-FINGERS aims to adapt,
test, and optimize the FINGER model to reduce risk across the spectrum of cognitive
decline—from at-risk asymptomatic states to early symptomatic stages—in different
geographical, cultural, and economic settings. WW-FINGERS aims to harmonize and
adapt multidomain interventions across various countries and settings, to facilitate
data sharing and analysis across studies, and to promote international joint initiatives
to identify globally implementable and effective preventive strategies.
KEYWORDS

Alzheimer’s disease, cognitive impairment, dementia, lifestyle, multidomain intervention, prevention, randomized controlled trial, World-Wide FINGERS

INTRODUCTION

disorders that cause dementia. Indeed, delaying the onset of AD by
only a few years could substantially reduce its prevalence and related

Worldwide, nearly 50 million people are living with dementia.

human and economic burdens.2

Alzheimer’s Disease International (ADI) predicts this number will

Several studies published in recent years suggest a decline in the

reach nearly 82 million in 2030 and over 152 million in 20501 unless

age-adjusted incidence of dementia, with stable or reduced preva-

interventions are identified and implemented to prevent or delay

lence, in Western countries including the United States,3,4 Sweden,5,6

onset, slow progression, or stop Alzheimer’s disease (AD) and other

the United Kingdom,7 and The Netherlands.8 Other studies, however,
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indicate an increased incidence in some Asian countries, such as
China and Japan.9-12 Factors that may have contributed to a lower

RESEARCH IN CONTEXT

occurrence of dementia in some countries relate to changes in risk factor profiles, including improved treatment for hypertension, diabetes,

1. Systematic review: The Authors met in 2 occasions (plus

and other vascular risk factors,13 as well as increased educational

additional teleconferences and smaller working-groups

opportunities.3 A meta-analysis of population-based observational

meetings) to discuss adaptation and testing of the FIN-

studies from the United States and Europe concluded that about 30%
of AD cases may be attributable to seven potentially modifiable risk
factors for AD—diabetes, midlife hypertension, midlife obesity, physical inactivity, depression, smoking, and low educational attainment.14
This study and others have concluded that targeting these risk factors
may represent a powerful strategy for risk reduction of AD. Given the
complex, multifactorial, and heterogeneous nature of late-onset AD
and dementia, interventions targeting several risk factors and mechanisms simultaneously may be required to achieve optimal preventive
effects.15
The Finnish Geriatric Intervention Study to Prevent Cognitive
Impairment and Disability (FINGER, ClinicalTrials.gov: NCT01041989)
represents the first large, long-term randomized controlled trial (RCT)
demonstrating that a multidomain lifestyle intervention can improve
cognitive function in older adults from the general population who are
at elevated risk of developing dementia.16 Participants in the trial were
randomized to either a group that received general health advice or a
group to be enrolled in a 2-year multidomain intervention that incorporated dietary counseling, physical exercise, cognitive training, and vascular and metabolic risk monitoring.17 Improvement in global cognition
after 24 months, assessed using the comprehensive Neuropsycholog-

GER multidomain prevention model in different settings
and populations. The development of a scientific methodology was supported also by search (PubMed, Authors’
own reference catalogues) for RCTs to prevent cognitive
impairment or dementia, which target multiple lifestyle
factors simultaneously. Ongoing and completed trials
were identified and discussed. These studies are appropriately cited.
2. Interpretation: The FINGER model has shown beneficial
effects on cognition in at-risk seniors. The model needs to
be further tested, adapted and optimized in diverse geographical and cultural settings. Within the World-Wide
FINGERS Network, a scientific methodology has been
outlined towards this goal.
3. Future directions: Ongoing and planned trials within the
World-Wide FINGERS Network will investigate feasibility and efficacy of the FINGER intervention in different populations, and generate data for evidence-based
knowledge for globally implementable and effective preventive strategies for cognitive impairment, dementia
and AD.

ical Test Battery (NTB total score), was 25% higher in the multidomain
intervention group than in the general health advice group (P = .03).
Performance was improved in all cognitive sub-domains including
executive function, processing speed, and complex memory tasks.16
Further analyses showed that the FINGER multidomain intervention

HIGHLIGHTS

benefited cognition regardless of sociodemographic and socioe-

∙ Prevention is pivotal to reduce the occurrence of dementia

conomic factors or other baseline characteristics, supporting the
potential benefits of the FINGER model for large at-risk populations.18

worldwide
∙ The Finnish Geriatric Intervention Study to Prevent Cog-

Individuals with genetic susceptibility (apolipoprotein E gene (APOE)

nitive Impairment and Disability (FINGER) trial model sup-

ε4 carriers) showed cognitive benefits from the intervention.19 The

ports the benefits of multidomain lifestyle interventions
∙ The World-Wide FINGERS (WW-FINGERS) network is

FINGER intervention also reduced the risk of developing new chronic
diseases.20 Extended 5- and 7-year follow-up assessments have been
completed recently and data analysis is ongoing to measure the longterm effects of the intervention. Although the FINGER trial results
were encouraging, two other large multidomain RCTs—the French
Multidomain Alzheimer Preventive Trial (MAPT) and the Dutch Pre-

testing and adapting the FINGER model globally
∙ WW-FINGERS is a unique network supporting data harmonization and sharing
∙ WW-FINGERS can lead to effective and feasible dementia
preventive strategies

vention of Dementia by Intensive Vascular Care (PreDIVA)—reported
lack of effect on the primary outcomes.21,22 Remarkably, exploratory
subgroup analyses in both studies provided evidence that interventions yielded cognitive benefits in subpopulations of participants

these approaches in diverse geographical, economic, and cultural

with increased risk of dementia,21-23 highlighting the importance of

settings.

methodological issues such as selection of at-risk individuals, adequate

The Lancet Commission on Dementia Prevention, Intervention, and

timing and intensity of the interventions, and selection of appropriate

Care proposed a life-course model of dementia risk that reflects how

sensitive tools to detect changes in cognition. Overall, the potential

lifestyle factors across the lifespan contribute to dementia risk. They

of multidomain interventions for dementia risk reduction and preven-

estimated that interventions across the lifespan could theoretically

tion needs further validation, and there is a need to test and adapt

prevent more than a third of dementia cases. These interventions
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include increasing access to and quality of education in early life; treat-

intervention at an individual level but also stimulate social interaction

ing or reducing hypertension and obesity in midlife; addressing hearing

and peer support; prospective harmonization of cognitive outcomes (ie,

loss; and reducing smoking, depression, physical inactivity, social isola-

assessment of cognitive changes) as well as other outcomes; and use

tion, and diabetes in late life.24

of randomization to support balanced comparisons among interven-

In 2017, the National Institute on Aging (NIA) asked the National

tion conditions. The network includes investigator teams from around

Academies of Science, Engineering, and Medicine to convene a com-

the world, with the aim of building on “lessons learned” from previous

mittee to explore evidence regarding interventions with the poten-

studies and expand the knowledge on feasibility and efficacy of mul-

tial to prevent or slow cognitive decline and dementia. Although it

tidomain interventions for risk reduction and prevention of dementia

found insufficient high-strength evidence to justify a public health cam-

in diverse populations.27 At the time of the WW-FINGERS Network

paign to encourage people to adopt lifestyle interventions to prevent

meeting in 2019, over 25 countries had joined, and WW-FINGERS tri-

dementia, the committee acknowledged that this may reflect method-

als had been planned in several European countries, USA, China, Sin-

ologic inconsistencies across clinical studies. They also cited results

gapore, South Korea, Japan, and Australia. Currently, similar efforts

from the FINGER trial as providing promising data from a large and

are ongoing in Central and South America, Canada, India, and Malaysia

long-duration trial of a multidomain intervention, and they suggested

(Table 1 and Figure 1).

replication of FINGER through multiple independent studies testing

WW-FINGERS comprises studies at different stages of implemen-

the same components.25 In addition, dementia risk reduction is one

tation and with varying gradations of alignment to the FINGER trial

of the strategic action areas of World Health Organization’s (WHO’s)

(Table 1). For instance, in the U.S. study to Protect Brain Health through

Global action plan on the public health response to dementia 2017-

a Lifestyle Intervention to Reduce Risk (U.S. POINTER), the interven-

2025. The recently published WHO Guidelines for risk reduction of

tions and outcomes are harmonized with FINGER. This consistency will

cognitive decline and dementia provide evidence-based recommenda-

allow for numerous cross-study comparisons as data become available

tions to support countries as they develop approaches to delay or pre-

in U.S. POINTER. A number of feasibility studies are evaluating the

vent the onset of dementia. The guidelines highlight the importance of

ability to conduct such a trial in a particular country and/or popula-

further research on the efficacy of multidomain interventions that are

tion, whereas other studies are in the initial stages of discussion and/or

adjusted to specific geographical and cultural contexts.26

implementation (Table 1 and Figure 1). To help classify and understand

In line with these indications, the launch of the World-Wide

the status of the WW-FINGERS trials, the network has agreed on the

FINGERS (WW-FINGERS) Network was announced at the 2017

definition of four main levels, which reflect the trials’ key features,

Alzheimer’s Association International Conference (AAIC) in London.27

including current status (eg, from RCTs still in the planning stage to

The Network aims to test the FINGER multidomain lifestyle model

those in which follow-up of participants is available); funding availabil-

in various populations and settings. Harmonization across trials is

ity; and degree of alignment with the FINGER RCT, in terms of design,

paramount, yet adaptations will be needed to ensure acceptance

intervention being tested, and assessment of cognitive outcomes (Fig-

of and adherence to interventions, as well as assessments among

ure 2). Each study in the WW-FINGERS Network can be assigned to a

populations that are appropriate in terms of language, ethnicity,

level, and movement among levels is expected.

culture, environment, and risk of AD and dementia. The WW-FINGERS

The next sections summarize the WW-FINGERS Network studies

Network held two face-to-face meetings in connection with AAIC: the

(see also Table 1), followed by a section discussing the key issue of data

first on July 20, 2018, in Chicago, and the second on July 12, 2019,

sharing and harmonization, and a final section on future steps needed

in Los Angeles. Periodic teleconferences and ancillary meetings have

to advance the Network activity.

been also held regularly to move forward with the Network activities.
This report summarizes the proceedings of the first two face-toface meetings, which are now repeated yearly in connection with

2.1

U.S. POINTER

AAIC.
In the United States, the U.S. POINTER study (ClinicalTrials.gov:
NCT03688126) will enroll approximately 2000 cognitively normal

2

WW-FINGERS NETWORK STUDIES

adults who are at an increased risk for cognitive decline and dementia in later life. Increased risk is defined by sedentary lifestyle, poor

WW-FINGERS was established to support and convene global multido-

diet, and other factors such as suboptimal cardiovascular health sta-

main dementia prevention trials, share experiences and data, as well

tus and first-degree family history of significant memory impairment.

as harmonize methods. The aim is not to replicate the original FIN-

At five sites across the country, participants will be randomly assigned

GER intervention, but rather to adapt and optimize it to various set-

to a self-guided or structured lifestyle intervention program focused

tings, to test whether FINGER-based protocols are feasible and effec-

on increasing physical exercise, consuming a healthy diet, intellectual

tive in various populations. Methodological pillars of WW-FINGERS

stimulation and social engagement, and health monitoring to man-

trials include: assessment of a multidomain intervention aiming to ame-

age cardiovascular risk factors. The primary outcome is change in

liorate vascular, metabolic, and lifestyle-related factors; delivery of the

global cognition, assessed by a composite score that is harmonized

intervention through individual and group sessions to optimize the

with the primary outcome in FINGER. Other measures will include

Population

1260 at-risk (CAIDE
score) adults aged
60-77

2000 at-risk, cognitively
normal adults age
60-79

3000 non-demented
adults age 60-79 at 52
villages in Western
Shandong province

6236 adults age 55-77
with two or more
dementia risk factors

900 adults age 55-75 at
two sites

FINGER (Finland)

U.S. POINTER (USA)

MIND-CHINA (China)

MYB (Australia)

AU-ARROW (Australia)

WW-FINGERS Network Studies

Study

TA B L E 1
Interventions

1. Passive health
education and
support
2. Active health
education and
support
3. Multidomain lifestyle
intervention

1. Non-interactive
web-based advice via
internet
2. Personalized modular
internet-based
multidomain coaching
in four thematic areas

1. Regular health care
services
2. Vascular intervention
3. Multidomain
intervention

1. Self-guided lifestyle
intervention
2. Structured lifestyle
intervention

1. Regular health advice
2. Intensive
multidomain
intervention

Global cognitive
composite score

Global cognitive
composite score

2 years

Blood and CSF biomarkers, brain and retinal
imaging

Dementia incidence; change in dementia risk
score (ANU-ADRI-SF); change in cognitive
domain scores and individual cognitive
tests; risk factor reduction (BMI, hip-waist
ratio, level of physical activity; physical
functional level, new chronic health
conditions, adherence to Mediterranean
diet, alcohol and smoking status, mental
activity levels, psychological distress);
service utilization (hospital admissions,
medical and social care services, prescribed
medications); study adherence; module
expectations, adverse events

Physical function, incident MCI and dementia
at 5 years, cardiovascular events
Brain MRI sub-study (3DT1, T2, FLAIR, SWI,
fMRI, MRA)

Global cognitive
composite

2 years
intervention,
extended
follow-ups

3 years

Vascular and metabolic status and events;
Walk Test and physical function; depressive
symptoms; quality of life; change in lifestyle
habits; APOE genotype
Sub-studies: brain imaging (MRI, amyloid and
tau PET); sleep; microbiome; vascular
function and structure

Global cognitive
composite, cognitive
domain-specific
composites (executive
function, episodic
memory)

2 years
intervention

Other assessments
Cognitive domains; functioning; vascular and
metabolic risk factors, morbidity and
mortality; disability; depressive symptoms;
quality of life; change in lifestyle habits;
utilization of health resources; blood
markers (eg, APOE, GWAS, telomere length,
metabolomics); brain imaging sub-study

Primary outcome
Global cognitive
composite

Trial duration
2 years
intervention,
extended
follow-ups

Study status

(Continues)

Funded,
recruitment
pending

Ongoing

Ongoing

Ongoing

Ongoing
extended
follow-up

KIVIPELTO ET AL .
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1. Usual care
2. Multidomain lifestyle
intervention
3. Multidomain lifestyle
intervention +
medical food
1. Original FINGER
intervention;
2. Culturally adapted
multidomain
intervention

120 adults with
prodromal AD plus
vascular and lifestyle
risk factors

70 seniors, age >65 with
mild-to-moderate
frailty and/or cognitive
impairment

150 adults, cognitively
normal, with at least
one modifiable risk
factor for cognitive
impairment
Age 60-79

440 adults with cognitive
impairment
(age-adjusted cognitive
scores <1.5 SD from
the reference value in
selected cognitive
domains) aged 65-85

125 at-risk (CAIDE score)
adults aged 60+ years

MIND-AD (Sweden,
Finland, France,
Germany)

SINGER (Singapore)

SUPERBRAIN (Korea)

J-MINT (Japan)

GOIZ-ZAINDU (Spain)
1. Regular health
services
2. Intensive
multidomain
intervention

1. Usual care
2. Multidomain
intervention

1. Facility-based
multidomain
intervention
2. Home-based
multidomain
intervention
3. Regular health advice
(subjects will receive
the multidomain
intervention after the
end of the study)

Interventions

Population

(Continued)

Study

TA B L E 1

Global cognitive
composite

Feasibility, adherence

1 year (pilot
intervention)

Feasibility, adherence

6 months
intervention

18 months
intervention

Feasibility, adherence

Feasibility, adherence

6 months +
optional
6-month
extension

6 months
intervention

Primary outcome

Trial duration

Global cognitive composite. Vascular and
metabolic risk factors (CAIDE score). 6
minutes walk test. Change in life habits.
Adherence to Mediterranean Diet. Quality
of life.

Cognitive domains; functioning
Geriatric assessment (frailty, polypharmacy,
comorbidities, lifestyle, subjective cognitive
complaints, poor sleep, depressive
symptom, social isolation, hearing
impairment, nutritional status/appetite)
Blood biomarkers for AD pathology and
neurodegeneration, and omics analysis
Brain MRI for structural analysis

Global cognition and memory, functional
status, depressive symptoms, quality of life,
nutritional status, change in levels of
motivation, physical function. Biological
studies on underlying mechanisms:
neurotrophic, neurodegeneration and
neuroinflammation factors, gut
microbiome, telomere length,
electroencephalography, neuroimaging

Physical activity and fitness, cognitive
performance, changes in body weight, BMI,
hip-waist-ratio, blood pressure, fasting
blood glucose and lipid, changes in blood
pressure management and medications

Vascular and metabolic factors; depressive,
anxiety and stress symptoms;
health-related quality of life; physical
performance; blood markers; cognition;
functioning; microbiome and brain imaging
sub-studies

Other assessments

(Continues)

Ongoing

Ongoing

Ongoing

Ongoing

Ongoing

Study status
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1. Directed educational
effort toward brain
health
2. Selected candidate
lifestyle interventions
3. Selected
pharmacological
interventions
1. Systematic
multidomain lifestyle
intervention
2. Flexible lifestyle
intervention

2024 non-demented
adults aged 60-85

1400 at-risk adults aged
60-77

Can Thumbs Up (Canada)

LATAM-FINGER
(Argentina, Brazil,
Bolivia, Chile,
Colombia, Costa Rica,
Cuba, Dominican
Republic, Ecuador,
Mexico, Paraguay,
Peru, Puerto Rico, and
Uruguay)

Global cognitive
composite

Feasibility and global
cognitive composite
(harmonized with
FINGER and U.S.
POINTER)

1-year
intervention

Protocol
development

Protocol
submitted

Surveys and remote assessments. IADL,
NPIQ, Geriatric Depression Scale, SF-36,
Gait, Single and Dual Task, PSQI, Research
Satisfaction
Blood-based biomarkers
Actigraphy cranial MRI

Cognitive domains
Subgroup analysis by APOE status, brain MRI
sub-study
Blood biobank established to test biomarkers

Recruiting

MRI and fMRI; microbiota;
neuroinflammation biomarkers;
metabolomics; blood, brain-derived
exosomes and CSF neuropathological
biomarkers
Physical activity, dietary assessments,
cognitive training performance and,
quality-of-life records

Global cognitive
composite
(ADCS-PACC-Plus-exe)

1-year (pilot)
intervention
and 3 months
follow-up after
discontinuing
intervention

Up to 5 years with
intermediate
futility analyses

Study status

Other assessments

Primary outcome

Trial duration

Key features of the WW-FINGERS Network studies in all levels that were presented during the face-to-face meetings. Additional studies around the world are in various stages of planning and initiation.
Abbreviations: AD, Alzheimer’s disease; ADCS-PACC, Alzheimer Disease Cooperative Study Preclinical Alzheimer Cognitive Composite; ANU-ADRI-SF, Australian National University Alzheimer’s Disease Risk
Index short form; APOE, apolipoprotein E gene; BMI, body mass index; CAIDE, Cardiovascular Risk Factors, Aging, and Incidence of Dementia; CSF, cerebrospinal fluid; EGCG, epigallocatechin gallate; fMRI,
resting state functional magnetic resonance imaging; GWAS, genome-wide association study; IADL, instrumental activities of daily living; MCI, mild cognitive impairment; MRA, Magnetic resonance angiography;
MRI, magnetic resonance imaging; NPI-Q, Neuropsychiatric Inventory–Questionnaire; PET, positron emission tomography; PSQI, Pittsburgh Sleep Quality Index; SD, standard deviation; SF-36, Short Form Health
Survey.

1. Multidomain lifestyle
intervention + EGCG
2. Multidomain lifestyle
intervention +
placebo EGCG
3. Usual care + EGCG
4. Usual care + placebo
EGCG

200 adults meeting
criteria of subjective
cognitive decline plus,
carriers of the APOE4
allele, 60+ years

PENSA (Spain)

Interventions

Population

(Continued)

Study

TA B L E 1
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F I G U R E 1 World map with countries that are involved in the World-Wide FINGERS Network. Dark blue indicates involvement in ongoing
World-Wide FINGERS studies. Studies are currently planned in countries marked with light blue

FIGURE 2

Levels defined for the trials participating in the World-Wide FINGERS Network

separate composite measures of episodic memory, executive func-

lected and stored for future investigations of potential mechanisms

tion, and processing speed; self-reported changes in mood, sleep, and

underlying intervention effects. Sub-studies will be conducted to col-

lifestyle practices; walking speed; and cardiometabolic health metrics.

lect magnetic resonance imaging (MRI) and amyloid and tau positron

Intervention effects will be examined by subgroups based on APOE ε4

emission tomography (PET); objective measures of sleep quality; and

genotype and baseline cognitive performance. Blood samples are col-

microbiome data. U.S. POINTER initiated recruitment in January 2019
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for the vanguard site in North Carolina. The other four sites include

ies, change in cognition is the primary outcome. Secondary out-

Northern California, Chicago (IL), Houston (TX), and Rhode Island. The

comes will include blood and cerebrospinal fluid (CSF) biomarkers and

Alzheimer’s Association funds the study and collaborates with the U.S.

brain imaging—amyloid and fluorodeoxyglucose PET, MRI, and retinal

POINTER Coordinating Center at Wake Forest School of Medicine

imaging.

(Winston-Salem, NC, USA) to assist in leading the study.

A
(MYB,

second

Australian

Australian

New

study,

called

Zealand

Maintain

Clinical

Your

Trials

Brain

Registry:

ACTRN12618000851268) is ongoing and tests an internet-based

2.2

MIND-CHINA

multidomain intervention, which if successful could provide a relatively low-cost strategy to deliver potentially preventive interventions

The randomized controlled Multimodal INtervention to delay Demen-

at a population level and in particular to geographically isolated people.

tia and disability in rural China (MIND-CHINA, Chinese Clinical Trial

To qualify for the study, individuals were 55- to 77-years-old and had

Registry: ChiCTR1800017758) study targets residents from 52 vil-

two or more lifestyle-related risk factors for dementia, including

lages in rural areas of Western Shandong Province (Yanlou Town of

physical inactivity, cognitive inactivity, depression/anxiety, overweight

Yanggu county). In March-October 2018, baseline assessments and

or obesity, and poor dietary habits.28 Participants (n = 6236) were

screenings for participants were completed, during which over 5700

randomized to receive a personalized multidomain intervention or

subjects who were 60 years of age or older were examined. Starting

non-interactive web-based health advice and information. A unique

from March 2019, non-demented and non-disabled residents aged 60

feature of the MYB trial is that the intervention is targeted to improve

to 79 are being enrolled into the MIND-CHINA Study and randomly

participant-specific risk factors. The interventions are delivered in the

divided by village (a method known as cluster randomization) into

form of coaching modules across four thematic areas: physical activity,

one of three groups: a group that will receive regular health care

diet and nutrition, cognitive training, and mood, and participants do

services provided by government; a vascular intervention group that

not need to receive the intervention in all four areas. Modules are

will receive intensive medical treatment to improve the control of

delivered quarterly in Year 1 followed by monthly boosters until end

three major vascular risk factors (high blood pressure, high blood

of Year 3. Primary outcomes include a cognitive composite measure, in

glucose, and dyslipidemia); or a multidomain intervention group that

synergy with FINGER and U.S. POINTER.

will receive guidelines of healthy lifestyle and diet, physical exercise,
promotion of personalized leisure activities, as well as cognitive training, in addition to intensive management of major vascular risk factors.

2.4

Europe—MIND-AD

MIND-CHINA aims to recruit 3000 participants. A cognitive composite measure that involves memory, language, information processing

The FINGER protocol is also tested in Europe (Sweden, Finland, Ger-

speed, and executive function similar to FINGER’s NTB will be used

many, France) in the Multimodal Prevention Trial for Alzheimer’s

as the primary outcome. Secondary outcomes will include physical

Disease (MIND-ADmini, ClinicalTrials.gov: NCT03249688). MIND-

function, incident mild cognitive impairment (MCI) and dementia (after

ADmini is an ongoing pilot trial evaluating the feasibility of the FINGER

5 years of follow-up), and occurrence of cardiovascular events. In addi-

multidomain lifestyle intervention in prodromal AD defined according

tion, a brain MRI sub-study is planned within MIND-CHINA, with core

to the International Working Group (IWG)-1 criteria.29 Participants

MRI sequences including magnetic resonance angiography, structural

also have modifiable vascular or lifestyle-related risk factors.

MRI measures, and resting-state functional MRI. MIND-CHINA is

Conducting a feasibility trial in people who are already in the early

supported by the grant from the National Key R&D Program of China

stages of AD and have some cognitive impairment is important because

and the Sino-Sweden joint research project grants from the National

of the potential need for additional support with healthy lifestyle main-

Natural Science Foundation of China and the Swedish Research

tenance. The duration of the trial is 6 months, with an optional 6-month

Council.

extension. Participants are randomized into three groups: multidomain lifestyle intervention based on the FINGER model; multidomain
lifestyle intervention plus the medical food Fortasyn Connect; or

2.3
Brain

Australia—AU-ARROW and Maintain Your

standard care. The rationale for combining a multidomain intervention
with medical food is suggested by studies that evaluate the synergistic
effects between different intervention components (eg, omega-3

Australia includes two lifestyle intervention studies that comprise dif-

fatty acids and physical activity). Fortasyn Connect is a multinutrient

ferent interventions and outcomes. One is the AUstralian-Multidomain

including omega-3 fatty acids, phospholipids, choline, vitamins, and

Approach to Reduce Dementia Risk by PrOtecting Brain Health with

minerals. It has been selected for MIND-AD because prior results from

Lifestyle intervention (AU-ARROW), which will randomize 900 par-

another phase-2 RCT in prodromal AD suggest that a combination of

ticipants ages 55 to 75 into one of three groups: a usual care

interventions should be evaluated.30

group; a group that will receive health education and support; and

The main aims of MIND-ADmini are to evaluate the feasibility of and

a multidomain intervention group. The trial will run for 2 years,

adherence to the multidomain intervention. Exploratory aims include

with an additional 6-month follow-up. As with other FINGER stud-

intervention effects on changes in vascular and metabolic risk factors;
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depressive, anxiety, and stress symptoms; cognition; health-related

2.7

Japan—J-MINT

quality of life; and physical performance. Blood samples are collected
for exploring potential mechanisms and mediating pathways of the

The Japan-multimodal intervention Trial for prevention of dementia

multidomain intervention. There is also a qualitative interview study

(J-MINT, UMIN Clinical Trials Registry: UMIN000038671) is an RCT

focusing specifically on the experiences of the trial participants. Results

that tests the effect of a multidomain intervention in subjects with

will be used in the planning of future larger trials and will serve as a

some degree of cognitive impairment (Table 1). The study will recruit

model for combining non-pharmacological and pharmacological inter-

440 older people (65- to 85-years-old) with a high risk of dementia,

ventions.

defined as decreased cognitive performance in at least one of the four
cognitive functional domains of memory, attention, executive function,
and processing speed. Subjects will be randomized to either a group

2.5

Singapore—SINGER

that receives usual care or a group that participates in an 18-month
multidomain intervention, consisting of exercise, nutritional counseling

The SINGapore GERiatric intervention study to reduce physical frailty

(visits and telephone follow-ups by health consultants with expertise

and cognitive decline (SINGER) is a pilot study aiming to evaluate cul-

in nutrition), and cognitive training using the “Brain HQ” program. In

turally appropriate adaptations of the FINGER interventions, and the

the exercise program, the intervention group participates in activities

feasibility of implementing this protocol in 70 seniors, aged >65 years,

described as “cognicise,” from the combination of the words “cognition”

with mild-to-moderate frailty and/or cognitive impairment over a 6-

and “exercise”—a program developed at the National Center for Geri-

month period (Table 1). The main outcome of this pilot study is the fea-

atrics and Gerontology, NCGG in Japan, which combines physical exer-

sibility of and adherence to the multidomain intervention, as concerns

cise and cognitive tasks. In addition, diabetes, hypertension, and dys-

have been raised particularly about the dietary and cognitive interven-

lipidemia are treated in accordance with the Japanese guidelines for

tions, which could require novel and culturally appropriate approaches.

older patients.

The aim is to develop scalable digital platforms and build partner-

The primary outcome of J-MINT is cognition, whereas the sec-

ships in order to conduct a larger confirmatory RCT in 1200 elderly

ondary outcomes include functional status, blood-based biomarkers

community-dwelling Singaporeans who are at risk of cognitive impair-

reflecting amyloid beta (Aβ) accumulation in the brain, omics analysis,

ment and dementia. This larger study, comparing self-guided lifestyle

and neuroimaging (MRI). Evidence from this research is expected to

management versus a structured multidomain lifestyle intervention,

inform a large-scale, national implementation of multidomain interven-

will also incorporate neuroimaging and blood biomarkers to investigate

tion programs for older people at high risk of dementia.

mechanisms of action.

2.8
2.6

Spain—GOIZ-ZAINDU and PENSA

South Korea—SUPERBRAIN
GOIZ-ZAINDU (Basque words for “caring early”) is an ongoing pilot

The SoUth Korean study to PrEvent cognitive impaiRment and pro-

RCT that tests the feasibility of the FINGER multidomain intervention

tect BRAIN health through lifestyle intervention in at-risk elderly

model in the Basque population in Spain. Participants, age 60+ years,

people (SUPERBRAIN, ClinicalTrials.gov: NCT03980392) is a mul-

have been recruited within the GOIZ-Alzheimer cognitive decline early

ticenter feasibility study enrolling seniors (60 to 79 years) with at

detection program, using inclusion criteria similar to those used in the

least one modifiable risk factor for dementia. The study includes

FINGER RCT: increased risk of dementia, based on a CAIDE (Cardio-

two intervention arms—facility-based intervention and home-based

vascular Risk Factors, Aging, and Incidence of Dementia) Dementia

intervention—as well as a group receiving regular health advice. The

Risk score of six points or higher,31 and lower-than-expected cogni-

24-weekmultidomain intervention has been derived by the FINGER

tive performance in at least one of three brief cognitive screening tests

model and includes five components: monitoring and management

(AD8 questionnaire, Fototest, memory alteration test).32-34 Since the

of metabolic and vascular risk factors; cognitive training and social

RCT started in June 2018, over 250 participants have been screened,

activity; physical exercise; nutritional guidance; and motivational

and 125 fulfilled the inclusion criteria. Stratification by cognitive sta-

enhancement. The trial aims to assess the feasibility of the multido-

tus (MCI and normal cognition) and age (75 or older) has been per-

main intervention, and includes as secondary outcomes disability,

formed before randomization to a multidomain intervention or to a

depressive symptoms, quality of life, vascular risk factors, physical

group receiving standard health advice. The multidomain intervention

performance, nutritional assessment, and a motivation questionnaire.

lasts 1 year and includes nutritional counseling, physical activity, cog-

To investigate mechanisms underlying the intervention, neurotrophic,

nitive training, and monitoring of vascular risk factors. The study will

neurodegeneration, and neuroinflammation factors, gut microbiome,

be completed by June 2020, and the outcomes include adherence to

telomere length, electroencephalography, and neuroimaging measures

the intervention, change in the CAIDE risk score, and global cognition,

will be evaluated. Based on the study results, a large-scale RCT will

measured with the NTB. Results from this pilot study will pave the

be launched to assess the effects of the multidomain intervention on

way to larger efficacy trials in the Basque country to provide knowl-

cognition.

edge for public health strategies on healthy-active aging and dementia
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prevention. The GOIZ-ZAINDU project is performed and funded by the

2.10

South and Central America—LatAm FINGER

CITA-Alzheimer Foundation in collaboration with the Municipality of
Beasain and Osakidetza (the public Basque Health System).

LatAm-FINGERS is a Latin American initiative gathering 14 countries—

Another study in Spain, the “Prevention of cognitive decline

Argentina, Bolivia, Brazil, Chile, Colombia, Costa Rica, Cuba, Domini-

after a multimodal intervention combined with epigallocatechin gal-

can Republic, Ecuador, Mexico, Paraguay, Peru, Puerto Rico, and

late in APOE4 carriers with subjective cognitive decline” (PENSA

Uruguay—and is open to incorporating other regional initiatives. The

study: in Catalan PENSA means “think about”; ClinicalTrials.gov:

consortium is developing a multidomain RCT that will enroll 1400

NCT03978052) is an ongoing project in Barcelona, performed in

individuals (100 from each country) aged 60 to 77 years, who are

collaboration with the Hospital del Mar Medical Research Institute

at a high risk of cognitive deterioration due to sedentary lifestyle

(IMIM) and the BarcelonaBeta Brain Research Center (BBRC). PENSA

and to suboptimal metabolic-cardiovascular profile. Subjects will

will randomize 200 individuals meeting criteria of subjective cogni-

be randomized to either a Systematic Lifestyle Intervention (SLI)

tive decline (SCD), fulfilling four SCD plus features, including sub-

or a Flexible Lifestyle intervention (FLI). The SLI group will receive

jects older than 60 years and APOE4 carriers. The project combines a

dietary counseling, physical exercise, cognitive training, and control

multidomain lifestyle intervention including diet, physical activity, and

of cardiovascular risk factors. The FLI group will receive regular

cognitive stimulation and training and the administration as dietary

health advice. Outcomes will be measured every 6 months and will

supplement of the flavanol from green tea, epigallocatechin gallate

include clinical and neuropsychological assessment harmonized with

(EGCG, 5 to 6 mg/kg up to 532 mg/day). The intervention will last

the original FINGER and with the U.S. POINTER. The protocol also

12 months. Participants will be randomized into one of four study

includes collection of blood samples and MRI data for the creation

arms (Table 1), and the primary outcome is global cognition mea-

of a biobank for future research. The LatAm FINGERS has two main

sured with the ADCS Preclinical Alzheimer Cognitive Composite-Plus-

objectives: first, to evaluate the feasibility of the FINGER multidomain

exe. Secondary and exploratory outcomes include neuroimaging (struc-

lifestyle intervention in the Latin American context; second, to eval-

tural and functional MRI); microbiota; neuroinflammation biomarkers;

uate the efficacy of the SLI, primarily on a global cognition composite

metabolomics; blood, brain-derived exosomes, and CSF neuropatho-

score as well as on specific cognitive domains: episodic memory,

logical biomarkers; physical activity, dietary assessments, cognitive

executive function, and processing speed. Analyses of the intervention

training performance, and quality-of-life records. The project is primar-

effects will consider the participants’ baseline cognition and APOE

ily funded by the Alzheimer’s Association, with additional support from

genotyping status. LatAm-FINGERS will allow to share, compare, and

the Spanish Ministry of Science, Innovation and Universities (Instituto

harmonize data across the participating centers, thus consolidating

Carlos III).

methods throughout Latin America for future collaborative research in
dementia.

2.9

CANADA—CAN-Thumbs-UP
2.11

India FINGER

In Canada, the Canadian Therapeutics Platform Trial for Multidomain Interventions to Prevent Dementia (CAN-Thumbs-Up) is in

Two longitudinal cohort studies of aging—one in an urban population

development and will include the recruitment of a platform trial-

and one in a rural population—are being carried out in India. In urban

ready cohort of participants identified as being at increased risk

Bangalore, adults 45 years or older are enrolled in a study funded by

of dementia. This cohort will initially participate in an online Brain

the Tata Trusts, while in the rural Kolar district, adults 45 years or older

Health Support Program (BHSP) for up to 1 year, aimed at improv-

are enrolled in the Srinivaspura Aging, Neuro Senescence and COGni-

ing dementia literacy, self-efficacy, and engagement. It will include

tion (SANSCOG) study. Similar assessments are used in both studies,

remote assessments during the BHSP that will enable evaluation

including a cognitive battery comparable to that used in FINGER and

of compliance, and changes in lifestyle through this educational

adapted for culture and education across India, brain MRI and PET, bio-

intervention. The platform trial-ready cohort data will support the

chemical tests with a focus on micronutrient deficiency and vascular

modeling of clinical and biomarker trajectories of the high-risk par-

risk factors, carotid Doppler ultrasonography, complete genetics, and

ticipants, who initially will either be cognitively normal or have MCI.

activity monitoring with wearables. The contrasts observed between

These data will inform development of the master trial protocol

the urban and rural populations will help inform a future FINGER-

as well as permitting identification and tailoring of interventions

type intervention study. These populations differ across many domains,

to high risk study groups. The open platform trial will particularly

including education, language, socialization, prevalence of cardiovas-

focus on testing multidomain interventions, including treatments of

cular risk factors, and nutritional deficiencies. For example, rural resi-

lifestyle, pharmaceuticals, and other types of combination treatments

dents may be reluctant to accept dietary modification and structured

in periods of up to 3 years. The primary outcome for the platform

exercise programs, but there may be more acceptance of yoga as a

trial is expected to be a global cognitive composite, with a range of

physical activity. Thus, a 6-month pilot study in 100 participants will

secondary and exploratory measures including blood-based and digital

investigate whether the practice of yoga affects cognitive and imag-

biomarkers.

ing end points. These observational studies are paramount so that
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population level data can be collected before moving into an interven-

accepted data standards, templates, and common data elements. Com-

tion phase.

mon data elements enable linkage of data across multiple studies,
increase the consistency and quality of data, facilitate comparisons,
drive efficiencies, and promote interoperability. In WW-FINGERS, har-

2.12

Other WW-FINGERS studies

monization will also be promoted in study design, enrollment criteria,
selection of interventions and outcomes, and monitoring of interven-

In Europe, a joint EURO-FINGERS protocol is currently being devel-

tion adherence. Members of the WW-FINGERS Network recognize the

oped to aid various European countries (eg, The Netherlands, Spain,

need to establish rigorous standards and harmonize these elements

the UK, Italy, Sweden) in establishing FINGER-like studies. Some of

before the studies begin data collection. Prospective harmonization of

the new trial design elements that may be tested include, for example,

the WW-FINGERS trials is being detailed in the WW-FINGERS Harmo-

utilizing e-health and mobile-health (m-health) tools and tailoring the

nization Protocol, which is currently under development. Among the

interventions to take into account specific risk profiles and combining

key points, the Protocol specifies that in all trials the main principles of

a multidomain lifestyle-based intervention with pharmacological

the intervention are based on the experiences from the FINGER study.

interventions. Encouraging results, in terms of acceptability and effi-

It is recommended that all the basic components of the multidomain

cacy of e-health interventions for dementia risk reduction, have been

intervention available in the FINGER study should be implemented;

recently reported in the European Healthy Aging Through Internet

that is, dietary counseling, physical exercise, cognitive training, and vas-

Counselling in the Elderly (HATICE, ISRCTN48151589). In this 18

cular and metabolic risk monitoring. At the same time, local and cultural

month multinational RCT, a coach-supported internet-based multido-

adaptations of the content and delivery method of the intervention are

main intervention for self-management of vascular and metabolic

encouraged. For instance, dietary counseling will follow national rec-

risk factors was tested in 2724 seniors, and the intervention was

ommendations while considering country- or region-specific habits. In

associated with a modest improvement of the risk profile.35,36

MIND-China, for example, dietary guidance puts special emphasis on

Still in Europe, Germany is assessing key issues related to the

reducing salt intake, which is a key dietary challenge in China. In India,

implementation of the FINGER model, in a pragmatic 2-year trial

yoga might be promoted to increase physical exercise, as it is commonly

(AgeWell.de, German Clinical Trials Register DRKS00013555)

practiced in some regions. In addition, pharmacological vascular risk

enrolling 1152 at-risk seniors through general practitioners.37 In addi-

factor management, when applicable, will be based on national care

tion, Malaysia is starting the Multidomain Intervention for Reversal of

guidelines. This is essential to improve engagement and adherence, and

Cognitive Frailty (AGELESS) study.

subsequently, to facilitate the effective and sustainable implementation of preventive strategies.
The Harmonization Protocol indicates that similar tools to detect

3
HARMONIZATION OF TRIALS, DATA
SHARING, AND ALIGNMENT

cognitive changes are recommended in all new WW-FINGERS trials.
When this is not possible, test batteries similar to the original but
validated in the local settings can be used. There is also the possi-

WW-FINGERS promotes the prospective harmonization of methods

bility for new cognitive outcome scores to be added (eg, in the U.S.

and outcomes across studies and responsible sharing of data. This will

POINTER, some cognitive computer-based measures have been added

enable joint analyses and comparisons across studies and will generate

as exploratory outcomes). Change in a global measure of cognitive

robust evidence to inform dementia prevention strategies. The power

function is the primary efficacy outcome in WW-FINGERS trials, but

of WW-FINGERS can only be realized through data sharing. In the

direct translation of cognitive assessments tools into different lan-

AD field, open and responsible data sharing has fueled tremendous

guages and in a manner that is relevant to different cultures and pop-

progress in the Alzheimer’s Disease Neuroimaging Initiative (ADNI),

ulations may not always be possible or feasible. In addition, educa-

as well as in four prevention studies that came together under the

tion can influence factors for cognitive assessment and performance. It

umbrella of the Collaboration for Alzheimer’s Prevention (CAP).38 Rec-

may be possible, however, to harmonize cognitive outcomes across dis-

ommendations to promote responsible data sharing were also adopted

parate populations with respect to the cognitive domains tested. In the

by a European task force through a consensus-building process.39

FINGER study, the major domains assessed included processing speed,

A vision for data sharing in WW-FINGERS has been adapted from

executive function, and episodic memory. Given cultural differences in

data.40

the WW-FINGERS Network, assessment of these domains may involve

These principles include (1) establishing a culture of sharing with incen-

administration of different cognitive tests. Another approach might

tives for sharing data; (2) building a global platform for sharing data;

be to administer a test that assesses everyday functional memory (as

(3) establishing best practices for data sharing; (4) providing adequate

opposed to rote memory) in ways that are more culturally relevant to

financial support for the sharing of data and allocating the costs among

individuals under study.

the Institute of Medicine (IOM) report on sharing clinical trial

all stakeholders; and (5) minimizing the risks and reducing disincentives
for data sharing.

It should be emphasized that the WW-FINGERS is not a single study
with multiple centers around the world, with unified strict criteria on

Integrating data from different RCTs and cohort studies into a

harmonized outcomes and interventions. Instead, the aim is to test

shared database requires that data are harmonized using existing and

the adaptation of the FINGER study in different populations regarding
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feasibility and effectiveness. Thus, the studies in the WW-FINGERS are

countries, targeting subjects with different risk profiles, either with-

separate studies with their own research questions with pooled data

out cognitive impairment or with pre-dementia symptomatic cognitive

analyses enabled through prospective harmonization, which increases

changes. Multidomain strategies have already been proved effective

power and permits subgroup analyses. Indeed, one of the key goals

and are internationally implemented in guidelines for the prevention

in the WW-FINGERS is to incorporate diversity, and inclusion of his-

of cardiovascular disease and diabetes mellitus. This supports the scal-

torically underrepresented groups (eg, sex, race, ethnicity, education,

ability that is being developed through WW-FINGERS.

socioeconomic status) is highly encouraged. Pooled data from the WW-

Overall aims of the WW-FINGERS Network are aligned with the

FINGERS Network can provide insight into the potential of multido-

recent WHO guidelines for risk reduction of cognitive decline and

main lifestyle interventions to impact cognitive health and decline

dementia,26 in which the WHO recommends conducting multido-

across widely diverse populations.

main intervention trials similar to FINGER to define evidence-based

While full alignment of outcome measures across all WW-FINGERS

approaches to public health preventive interventions. This is espe-

trials could be challenging regarding cognition and lifestyle, it might

cially crucial for low- and middle-income countries (LMICs), which lack

be easier for brain imaging, blood and CSF biomarkers, and clinical

robust evidence on risk and protective factors for dementia and AD,

measures, for which substantial work toward standardization has been

and yet are expected to face the highest rise in the number of dementia

done. Omics and genome-wide association study data are relatively

cases by 2050.1 Toward this end, the Network has started working to

new in clinical trials and thus there has been less progress on harmo-

engage and support LMICs as well as other countries (eg, Middle East:

nization. The WW-FINGERS Network will work toward establishing

Israel, Iran; Africa: Cameroon, South Africa; Russia, Hungary), and the

global standards for sample collection and explore the potential of a

close collaboration with the WHO can help disseminating study find-

WW-FINGERS biorepository.

ings in these areas and potentially expand the WW-FINGERS Network.

Regarding the need for a data sharing platform, the WW-FINGERS

The WHO recognizes the need for research coordination and har-

Network will build upon prior work, as well as search for innovative

monization. In this regard, WW-FINGERS will provide insight on the

ICT-solutions (ie, Information and communications technology), gen-

challenges that need to be overcome to drive global collaborative

erated by the rapid expansion of data sharing technologies and tools.

efforts and the implications for research, ethics, and policy. A WW-

For instance, U.S. POINTER will use the Global Alzheimer’s Associa-

FINGERS Harmonization Protocol is being compiled, to ensure that

tion Interactive Network (GAAIN, gaain.org) as a platform for global

country-specific WW-FINGERS trials are harmonized with the core

data sharing, as GAAIN can link diverse data sets. ICT solutions can

features of the FINGER study, allowing for local adaptations to be

help overcome the challenges of having data cross country borders,

introduced. An Oversight Committee, described in the protocol, plans

harmonizing data sets, and allowing for aggregate interrogation in a

to oversee its proper implementation and guide the development of a

secure framework. As the WW-FINGERS Network expands and trials

set of common data elements, the synchronization of outcomes across

are launched, data-sharing tools will be assessed as it will be important

studies engaging diverse populations, and the building of an infrastruc-

for the various initiatives to align so that trial data are analyzed,

ture to support a network-wide data sharing.

interpreted, and validated in a consistent manner and that privacy and

In WW-FINGERS, the focus is on individual-based preventive

confidentiality are maintained. From the European perspective, given

approaches in persons with increased risk of dementia. Although WW-

the current changes in regulation regarding data protection (ie, Euro-

FINGERS is not designed to incorporate broader health care and social

pean General Data Protection Regulation, GDPR),41 sharing individual

policies, the pooled analyses will provide the opportunity to explore the

level data with countries outside of the European Union is difficult,

feasibility and effectiveness of interventions in different health care

even with proper pseudonymization.42 Therefore, instead of sharing

and social settings.

individual level data across the borders, the aim within the WW-

Results from WW-FINGERS can be used to potentially update the

FINGERS Network is to create a federated database platform enabling

WHO recommendations specifically relating to multidomain interven-

pooled data analyses remotely.43 Overall, WW-FINGERS aims to

tions, and findings from WW-FINGERS trials can be disseminated

optimize harnessing of data, while accounting for global variations and

though the WHO’s Global Dementia Observatory (GDO), a data and

increasing requirements for data protection and sharing.

knowledge exchange platform that offers easy access to key dementia data from Member States across the following three domains: policies, service delivery, and information and research. The GDO supports

4

NEXT STEPS

countries in measuring progress on dementia actions outlined in the
Global Dementia Action Plan on the Public Health Response to Demen-

WW-FINGERS is the first global network of multidomain lifestyle inter-

tia 2017-2025 and assists them in strengthening policies, service plan-

vention trials for dementia risk reduction and prevention, and aims

ning, and health and social care systems for dementia.44

to adapt, test, and optimize the FINGER model to prevent dementia

WW-FINGERS will offer numerous opportunities for hypotheses

across the entire spectrum of cognitive decline—from at-risk asymp-

testing, in addition to those assessing the efficacy of multidomain inter-

tomatic states to early symptomatic stages, such as prodromal AD—

ventions to slow cognitive decline. For example, several studies are

and in different geographical, cultural, and economic settings. Multi-

planning to investigate the relationship of vascular risk factors and vas-

ple WW-FINGERS studies are in the early stages of initiation in several

cular disease with dementia. In addition, the rich neuroimaging and
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biorepository collected will enable studies on mediating pathways and
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eration in Aging (CCNA) Phase 2, which is funded by the Canadian

underlying mechanisms of the multidomain interventions, as well as

Institutes of Health Research (CIHR #201901CNA-417847-CAN-

contribute to identifying risk profiles that may be more responsive to

ABPI- 32054) and a consortium of partners including the Alzheimer

specific interventions. Together with the introduction of pharmacolog-

Society of Canada. The work in India is made possible by funding

ical components within the multidomain lifestyle model, this approach

from Centre for Brain Research, Bengaluru, India. The PENSA study

can facilitate the definition of preventive approaches within the frame-

is funded by the Alzheimer’s Association (18PTC-R-592192) and the

work of precision prevention.

Instituto Carlos III (PI17/00223). MIND-CHINA was supported by the

By collectively convening several multidisciplinary research teams,

National Key R&D Program of China from the Ministry of Science and

WW-FINGERS will provide a forum to establish harmonization and

Technology of China (grant no.: 2017YFC1310100), and additional

encourage adaptation of the multidomain lifestyle intervention across

grants were received from the Shandong Taishan Scholar Program,

various countries and settings, facilitate responsible data sharing and

Shandong, China; the Sino-Sweden joint research project grants

analysis across studies, establish opportunities for joint initiatives

from the National Natural Science Foundation of China (NSFC grant

across country borders, and strengthen the potential evidence base

no.: 81861138008) and the Swedish Research Council (grants no.:

for multidomain lifestyle interventions to prevent cognitive decline and

2017-00740 and 2017-05819); and the Joint China-Sweden Mobility

dementia. The WW-FINGERS Network of studies will provide impor-

Programme grants from the National Natural Science Foundation of

tant new knowledge that will facilitate the development of effective

China NSFC (grant no.: 8191101618) and the Swedish Foundation for

interventions and contribute to identifying globally applicable strate-

International Cooperation in Research and Higher Education (STINT,

gies to prevent or delay the onset and progression of late-life cogni-

grant no.: CH2019-8320). GOIZ ZAINDU project has been partially

tive impairment, AD, and dementia. Risk factor modifications by public

financed by the Health Department of the Basque Government (File

health interventions have had a remarkable impact on the occurrence

No. 2017111120). Paulo Caramelli holds a senior research fellowship

of cardiovascular disease, and the same can be expected for dementia.

(bolsa de produtividade em pesquisa) from CNPq, Brazil. SUPERBRAIN
was supported by the grant from the Korea Health Technology R&D
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